Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Huang, Jia Jia ^a   Li, Ya Jun ^a   Xia, Yi ^a   Wang, Yu ^a   Wei, Wen Xiao ^a   Zhu, Ying Jie ^a   Lin, Tong Yu ^a   Huang, Hui Qiang ^a   Jiang, Wen Qi ^a   Li, Zhi Ming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Absolute monocyte count; Extranodal natural killer T cell lymphoma; Prognosis; Tumor microenvironment

Indexed keywords

ASPARAGINASE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PREDNISONE; VINCRISTINE;

ABSOLUTE MONOCYTE COUNT; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; KOREAN PROGNOSTIC INDEX; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; YOUNG ADULT;

EID: 84877005682     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-222     Document Type: Article

References (45)

1. Jaccard A, Hermine O. Extranodal natural killer/T-cell lymphoma: advances in the management. Curr Opin Oncol 2011, 23:429-435. 10.1097/CCO.0b013e328349aba6, 21743325.
2. Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008, 112:1425-1436. 10.1002/cncr.23316, 18286525.
3. Gill H, Liang RH, Tse E. Extranodal natural-killer/t-cell lymphoma, nasal type. Adv Hematol 2010, 201:627401.
4. Gualco G, Domeny-Duarte P, Chioato L, Barber G, Natkunam Y, Bacchi CE. Clinicopathologic and molecular features of 122 Brazilian cases of nodal and extranodal NK/T-cell lymphoma, nasal type, with EBV subtyping analysis. Am J Surg Pathol 2011, 35:1195-1203. 10.1097/PAS.0b013e31821ec4b5, 21716086.
5. Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, Dai L, Liu WP. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol 2011, 6:77. 10.1186/1746-1596-6-77, 3179701, 21854649.
6. Li ZM, Zhu YJ, Sun J, Xia Y, Huang JJ, Zou BY, Lin TY, Huang HQ, Jiang WQ. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol 2012, 91:1265-1270. 10.1007/s00277-012-1434-1, 22373550.
7. Wang ZY, Li YX, Wang H, Wang WH, Jin J, Liu YP, Song YW, Wang SL, Liu XF, Yu ZH. Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. Ann Oncol 2011, 22:390-396. 10.1093/annonc/mdq347, 20616195.
8. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol 2012, 29:2183-2190. 10.1007/s12032-011-0030-x, 21786011.
9. de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology 2011, 58:49-68. 10.1111/j.1365-2559.2010.03704.x, 21261683.
10. Ham MF, Ko YH. Natural killer cell neoplasm: biology and pathology. Int J Hematol 2010, 92:681-689. 10.1007/s12185-010-0738-y, 21132576.
11. Li YX, Fang H, Liu QF, Lu J, Qi SN, Wang H, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Feng XL, Yu ZH. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of waldeyer ring. Blood 2008, 112:3057-3064. 10.1182/blood-2008-05-160176, 18676879.
12. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006, 24:612-618. 10.1200/JCO.2005.04.1384, 16380410.
13. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011, 117:872-881. 10.1182/blood-2010-05-283820, 3035079, 21063024.
14. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev 2008, 22:261-281. 10.1016/j.blre.2008.03.009, 18456377.
15. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323. 10.1056/NEJMoa0802885, 19038878.
16. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169. 10.1056/NEJMoa041869, 15548776.
17. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011, 118:2659-2669. 10.1182/blood-2011-05-326538, 21700770.
18. De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer 2008, 112:407-415. 10.1002/cncr.23168, 18058809.
19. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 2011, 22:149-155. 10.1093/annonc/mdq314, 20595450.
20. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007, 21:2227-2230. 10.1038/sj.leu.2404780, 17554383.
21. Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol 2011, 4:34. 10.1186/1756-8722-4-34, 3170642, 21843362.
22. Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Markovic SN. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia 2007, 21:2554-2556. 10.1038/sj.leu.2404819, 17581607.
23. Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI, Dietz AB, Novak AJ, Witzig TE, Feldman AL, Pittelkow MR, Ansell SM. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009, 114:2936-2944. 10.1182/blood-2009-05-220111, 2756204, 19671921.
24. Ishii H, Takahara M, Nagato T, Kis LL, Nagy N, Kishibe K, Harabuchi Y, Klein E. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15. Int J Cancer 2012, 130:48-58. 10.1002/ijc.25969, 21618217.
25. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011, 25:1502-1509. 10.1038/leu.2011.112, 21606957.
26. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012, 53:575-580. 10.3109/10428194.2011.637211, 22098403.
27. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci 2009, 100:2242-2248. 10.1111/j.1349-7006.2009.01319.x, 19758393.
28. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861. 10.1182/blood-2006-08-038257, 17105812.
29. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, . International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586. 10.1200/JCO.2006.09.2403, 17242396, International Harmonization Project on Lymphoma.
30. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005, 37:409-419. 10.1080/00313020500370192, 16373224.
31. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011, 21:293-298. 10.1016/j.semcancer.2011.09.010, 21945518.
32. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park) 2011, 24:936-944.
33. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008, 112:5150-5160. 10.1182/blood-2008-01-133587, 2597610, 18796628.
34. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005, 93:273-278. 10.1038/sj.bjc.6602702, 2361564, 16052222.
35. Lopez-Gonzalez JS, Avila-Moreno F, Prado-Garcia H, Aguilar-Cazares D, Mandoki JJ, Meneses-Flores M. Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-alpha. Clin Immunol 2007, 122:323-329. 10.1016/j.clim.2006.11.003, 17175197.
36. Hase S, Weinitschke K, Fischer K, Fornara P, Hoda R, Unverzagt S, Seliger B, Riemann D. Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep 2011, 25:1455-1464.
37. Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006, 24:1997-2005. 10.1200/JCO.2005.03.9594, 16648500.
38. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007, 179:977-983.
39. Miyauchi K, Urano E, Yoshiyama H, Komano J. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci 2011, 102:1236-1241. 10.1111/j.1349-7006.2011.01924.x, 21392167.
40. Moriai S, Takahara M, Ogino T, Nagato T, Kishibe K, Ishii H, Katayama A, Shimizu N, Harabuchi Y. Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 2009, 15:6771-6779. 10.1158/1078-0432.CCR-09-1052, 19887486.
41. Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 2011, 11:888-895. 10.1111/j.1600-6143.2011.03499.x, 21521464.
42. Datta S, Sarvetnick N. Lymphocyte proliferation in immune-mediated diseases. Trends Immunol 2009, 30:430-438. 10.1016/j.it.2009.06.002, 19699149.
43. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, Kanda Y, Hirokawa M, Kawabata Y, Matsumura T, Kusumi E, Hirabayashi N, Nagafuji K, Suzuki R, Takeuchi K, Oshimi K. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005, 130:561-567. 10.1111/j.1365-2141.2005.05651.x, 16098071.
44. Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C, Mukai H, Takenaka K, Yoshino T, Tsuzuki T, Sugimori H, Kawa K, Kodera Y, Oshimi K, . NK-cell Tumor Study Group Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006, 37:425-431. 10.1038/sj.bmt.1705244, 16400344, NK-cell Tumor Study Group.
45. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J, Sakai C, Oshimi K, Kwong YL, Liang R, Yiu H, Wong KH, Cheng HC, Ryoo BY, Suh C, Ko YH, Kim K, Lee JW, Kim WS, Suzuki R. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008, 14:1356-1364. 10.1016/j.bbmt.2008.09.014, 19041057.